Business
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES / ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS ("GEM"), the Company's share capital has increased o
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET","length":134,"tagName":"p"},{"type":"text","content":"Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS ("GEM"), the Company's share capital has increased on 26 March 2026 from EUR 7,948,543.35 to EUR 8,037,001.07 and the number of issued and outstanding shares has further increased from 76,720,045 to 77,573,884 ordinary shares, through the issuance of a total of 853,839 new shares at an issue price of (rounded) EUR 0.4698 per share to the benefit of GEM. The aforementioned capital increase has been completed in the framework of the settlement of a ninth subscription request notice issued by the Company to GEM under the share subscription facility agreement entered into on 17 March 2025 between a.o. the Company and GEM (the "Facility"), and which had been approved in principle by the Company's board of directors within the framework of the authorised capital on 8 April 2025. For more information about the Facility, reference is made to the Company's press release dated 18 March 2025 (which can be accessed here). The drawdowns within the Facility are extending the Company's cash runway into the second quarter of 2026.","length":1400,"tagName":"p"},{"type":"text","content":"The Company also announces today that it will issue a tenth subscription request notice in accordance with the terms of the aforementioned Facility. This subscription request notice is expected to be settled in...